登录新浪财经APP 搜索【信披】查看更多考评等级 针对公司股票交易异常波动，公司董事会对公司、控股股东及实际控制人就相关事项进行了核查，现就 有关情况说明如下： 1、经核查，公司前期披露的信息不存在需要更正、补充之处。 证券代码：002235 证券简称：安妮股份 公告编号：2025-040 厦门安妮股份有限公司 关于公司股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股票交易异常波动情况 厦门安妮股份有限公司（以下简称"公司"，证券代码：002235，证券简称：安妮股份）股票于2025年12 月10日和2025年12月11日连续2个交易日收盘价格涨幅偏离值累计超过20%，根据《深圳证券交易所交 易规则》的有关规定，属于股票交易异常波动情况。 二、公司关注并核实相关情况说明 经公司董事会确认，除前述事项外，本公司目前没有任何根据《深圳证券交易所股票上市规则》规定应 予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、协议等；董事会也未获悉本公司有根据 《深圳证券交易所股票上市规则》的规定应予以披露而未披露的、对本公司股票交易价格产 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 据记者梳理，此次嘉美包装控制权变更的筹划并非偶然。11月18日，嘉美包装披露控股股东中包香港、 大股东富新投资有限公司（以下简称"富新投资"）和中凯投资发展有限公司（以下简称"中凯投资"）的 联合减持计划，中包香港拟减持不超过0.16%股份，富新投资以及中凯投资拟合计减持不超过1%股份， 时隔一个月不到，嘉美包装便公告筹划控制权变更，或释放出控股股东以及大股东对该公司现有发展模 式的战略调整信号。 作为深耕食品饮料金属包装及灌装服务的企业，嘉美包装的客户涵盖养元饮品等知名品牌。今年前三季 度，嘉美包装实现营业收入20.39亿元，同比下降1.94%；归属于母公司所有者的净利润为3916.02万 元，同比下降47.25%。 "近年来，包装行业普遍面临成本压力与需求变革的双重挑战，原材料价格波动、消费端结构调整等因 素催化行业洗牌，行业集中度明显提升。"上海大学悉尼工商学院讲师王雨婷对《证券日报》记者表 示，在此背景下，通过控制权变更引入战略投资者，成为传统制造企业突破发展瓶颈的重要选择之一。 责任编辑：杨红卜 筹划控制权变更！这家公司继续停 ...

格隆汇12月11日丨南都电源(300068.SZ)公布，公司于近日收到公司控股股东杭州南都电源有限公司、 上海益都实业有限公司、上海南都集团有限公司通知，获悉其正在筹划控制权变更、促进再生铅板块股 权出售的相关事宜。目前各方尚未签署相关协议，拟就具体交易方案、协议等相关事项进行论证和磋 商，具体情况以各方签订的相关协议为准。鉴于上述事项尚存在重大不确定性，为保证公平信息披露， 维护投资者利益，避免公司股价异常波动，根据《深圳证券交易所创业板股票上市规则》及《深圳证券 交易所上市公司自律监管指引第6号——停复牌》的相关规定，经公司向深圳证券交易所申请，公司股 票（股票简称：南都电源，股票代码：300068）自2025年12月12日（星期五）开市起停牌，预计停牌时 间不超过2个交易日。 ...

Core Viewpoint - The company, Mengtian Home (603216), has announced the postponement of several fundraising investment projects to the end of December 2026, which is not the first time such delays have occurred [1][2]. Group 1: Fundraising Investment Projects - On December 10, the company held its third board meeting and approved the extension of the deadlines for the "R&D Center Platform Project," "Brand Channel Construction Project," and "Information Technology Construction Project" to December 2026, without changing the implementation subjects, methods, purposes, or scales of the fundraising projects [1]. - In December 2024, the company had previously announced a similar extension for other projects, including the "Annual Production of 370,000 Flat Doors and 90,000 Customized Cabinets Technical Reform Project" and "Intelligent Storage Center Construction Project," also to December 2026 [1]. Group 2: Financial Performance - The company has experienced a decline in revenue and net profit attributable to shareholders for two consecutive years in 2023 and 2024 [2]. - In the first three quarters of 2025, the company reported revenue of 777.3 million yuan, a year-on-year decrease of 2.93%, while the net profit attributable to shareholders was 56.3 million yuan, an increase of 37.60% [2]. Group 3: Major Asset Restructuring and Control Change - Recently, the company's major asset restructuring and control change plans were terminated, which attracted market attention [3]. - On November 18, the company announced plans to acquire control of Shanghai ChuanTu Microelectronics Co., Ltd. through a share issuance and cash payment, but the plans were ultimately abandoned after negotiations failed to reach a consensus [3]. - Following the announcement, the company's stock experienced significant volatility, achieving seven limit-up days in ten trading days from November 19 to December 2, before experiencing a price drop [3].

Core Viewpoint - The controlling shareholder of Jia Mei Packaging, Zhong Bao Hong Kong, is planning a change in control, which may lead to a change in the actual controller of the company. The stock will be suspended from trading starting December 10, 2025, for up to two trading days due to this uncertainty [2]. Group 1: Company Overview - Jia Mei Packaging is a platform enterprise serving beverage brands across the entire industry chain, providing R&D, design, production, and sales of beverage packaging containers, as well as beverage formula R&D, filling production, and marketing services [4]. - The company owns 17 subsidiaries covering various business segments, including tin printing, three-piece cans, two-piece cans, and various packaging materials for beverage filling OEM [4]. - Major clients include Yangyuan Beverage, Wanglaoji, Yinlu Group, Dali Group, Chengde Lulule, and Xiduo Duo, with Yangyuan Beverage being an associated party of the listed company [4]. Group 2: Shareholding and Stock Performance - As of September 30, 2025, Zhong Bao Hong Kong holds 44.75% of Jia Mei Packaging's shares, with Chen Min and Li Cuiling as the actual controllers [4]. - On November 18, Zhong Bao Hong Kong announced plans to reduce its holdings by up to 1.5 million shares, accounting for 0.16% of the total share capital [4]. - The second and third largest shareholders, Fu Xin Investment and Zhong Kai Investment, also announced plans to reduce their holdings by a total of approximately 9.34 million shares, representing 1% of the total share capital [6]. Group 3: Financial Performance - The company's net profit dropped to a record low of 17.03 million yuan in 2022, but showed significant recovery in 2023 and 2024 [9]. - However, in the first three quarters of 2025, Jia Mei Packaging's profitability weakened again, with total revenue of 2.039 billion yuan, a year-on-year decrease of 1.94%, and a net profit of 39.16 million yuan, down 47.25% year-on-year [9]. - The stock price has been rising recently, with a 16% increase over three trading days, including a limit-up on December 5 and a subsequent 7.80% increase [11]. Group 4: Current Market Position - As of December 9, 2025, Jia Mei Packaging's stock closed at 4.56 yuan per share, giving it a market capitalization of 4.36 billion yuan [12].

Group 1 - The company announced a suspension of trading due to a planned change in control and the issuance of shares to acquire assets [1] - The controlling shareholder, Qin Benjun, is negotiating to transfer part of his shares and relinquish voting rights, with agreements signed with major counterparties [1][2] - The transaction will result in Beijing Jinkangpu becoming a subsidiary of the company, included in the consolidated financial statements, and is expected to be an affiliated transaction [2] Group 2 - Guangzhou Defu Nutrition, the acquiring party, was established on December 2, 2025, and has a capital contribution of 1.35 billion yuan, with a significant majority from Guangzhou Defu Investment Management [2] - Beijing Jinkangpu, the target of the acquisition, specializes in food nutrition fortifiers and has been operational since 2004, serving various sectors including infant food and health supplements [2] - The company focuses on the production and operation of natural health products, with expertise in over 300 standardized plant extraction technologies and a range of products including monk fruit and stevia extracts [3] Group 3 - In the first three quarters of the year, the company reported revenue of 1.272 billion yuan, an increase of 8.73%, while net profit attributable to shareholders decreased by 30.73% to 70.3953 million yuan [3] - The transaction is expected to enhance the company's capabilities in product formulation and core competitiveness in the food and health supplement sectors, leveraging synergies between the two entities [3] - The collaboration aims to ensure a supply of natural raw materials and enhance global marketing capabilities, fostering a mutually beneficial development model [3]

秦本军先生及公司已与本次交易的主要交易对方广州德福营养、德福金康普控股有限合伙企业、厦 门德福金普投资合伙企业（有限合伙）分别签署了《控制权变更意向协议》《发行股份购买资产并募集 配套资金意向协议》，协议约定秦本军先生通过协议转让方式将其所持有的部分公司股份转让给广州德 福营养，并签署《表决权放弃协议》，自愿放弃其所持公司部分股份的表决权。同时公司拟向德福金康 普控股有限合伙企业和厦门德福金普投资合伙企业（有限合伙）发行股份购买其合计持有的北京金康普 80%股权，以及向广州德福营养发行股份募集配套资金。 交易标的相关股权的最终交易价格，以公司聘请的符合证券法规定的评估机构出具的评估报告结果 为定价依据，由交易各方协商确定。上述协议仅为交易各方就本次交易达成的初步意向，本次交易的具 体方案将由交易各方另行签署正式协议予以约定。 因上述交易尚处于筹划阶段，有关事项存在不确定性，为保证信息披露的公平，维护投资者利益， 避免对公司股票交易造成重大影响，根据《深圳证券交易所上市公司自律监管指引第6号—停复牌》等 有关规定，经公司申请，公司股票（证券简称：莱茵生物，证券代码：002166）自2025年12月10日（星 期 ...

明起停牌。 莱茵生物（002166）12月9日晚间公告，公司于2025年12月8日收到控股股东、实际控制人秦本军的通知，秦本军正在筹划公司控制权变更 事宜。公司股票自2025年12月10日开市起停牌，预计停牌时间不超过10个交易日。 公告显示，秦本军及公司已与本次交易的主要交易对方广州德福营养投资合伙企业（有限合伙）（简称"广州德福营养"）、德福金康普控 股有限合伙企业、厦门德福金普投资合伙企业（有限合伙）分别签署了《控制权变更意向协议》《发行股份购买资产并募集配套资金意向 协议》，协议约定秦本军通过协议转让方式将其所持有的部分公司股份转让给广州德福营养，并签署《表决权放弃协议》，自愿放弃其所 持公司部分股份的表决权。上述事项可能导致公司控股股东及实际控制人发生变更。 同时公司拟向德福金康普控股有限合伙企业和厦门德福金普投资合伙企业（有限合伙）发行股份购买其合计持有的北京金康普食品科技有 限公司（简称"北京金康普"）80%股权，以及向广州德福营养发行股份募集配套资金。 本次交易完成后，北京金康普将成为公司的控股子公司，纳入合并财务报表范围。本次交易不构成重大资产重组及重组上市。 本次交易将北京金康普纳入上市公 ...

Core Viewpoint - Rhine Biotech (002166) announced a suspension of its stock trading starting December 10 due to plans for a change in control, issuance of shares, and cash payment for asset acquisition, with the suspension expected to last no more than 10 trading days [1] Group 1: Control Change - The controlling shareholder and actual controller, Qin Benjun, is planning to transfer part of his shares and relinquish voting rights [1] - A "Control Change Intent Agreement" has been signed with the counterparty, Guangzhou Defu Nutrition Investment Partnership (Limited Partnership) [1] Group 2: Acquisition Details - Rhine Biotech intends to acquire at least 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a combination of share issuance and cash payment [1] - Following the transaction, Beijing Jinkangpu will become a subsidiary of Rhine Biotech and will be included in the consolidated financial statements [1] - The transaction is not classified as a major asset restructuring or restructuring listing, but it is expected to constitute a related party transaction [1] Group 3: Company Background - Beijing Jinkangpu, established in 2004, specializes in the compounding, testing, sales, and technical development of food nutrition fortifiers [1] - Rhine Biotech's core products include natural sweeteners [1]

Core Viewpoint - Tai Long Pharmaceutical (600222.SH) has resumed trading after a significant shareholder change, with shares closing at 8.20 yuan, down 4.43%, and a total market capitalization of 4.706 billion yuan [1] Group 1: Shareholder Change and Stock Resumption - The company announced that its controlling shareholder, Tai Rong Chan Investment, is planning a share transfer that may lead to a change in control [1] - The stock was suspended from trading on December 2, 2025, and initially expected to resume on December 4, but continued to be suspended until December 9, 2025 [1] - The resumption of trading occurred after an agreement was reached regarding the share transfer [1] Group 2: A-Share Issuance - The company plans to issue A-shares to specific investors, aiming to raise up to 454.35 million yuan, which will be used for working capital and repaying interest-bearing debts [2] - The shares will be issued at a price of 6.09 yuan per share, which is not less than 80% of the average trading price over the previous 20 trading days [3] - The issuance will involve a maximum of 74,605,216 shares, representing 13% of the total share capital before the issuance [3] Group 3: Share Transfer Agreement - On December 8, 2025, Jiang Pharmaceutical Holdings signed a share transfer agreement with Tai Rong Chan Investment to acquire 50,100,000 shares, which is 8.73% of the total share capital before the issuance [4] - The share transfer will occur in two tranches, with the first tranche involving 42,300,000 shares and the second tranche involving 7,800,000 shares [4] - An action agreement was also signed, ensuring that Tai Rong Chan Investment and Jiang Pharmaceutical Holdings will act in concert regarding major decisions affecting the company [4] Group 4: Control Changes - Following the completion of the first share transfer and the action agreement, Jiang Pharmaceutical Holdings will become the controlling shareholder, with the actual controller being the Jiangxi Provincial State-owned Assets Supervision and Administration Commission [5] - Jiang Pharmaceutical Holdings will hold 42,300,000 shares, while Tai Rong Chan Investment will retain 40,141,168 shares, giving them a combined control of 82,441,168 shares, or 14.37% of the total share capital [6] - The issuance of A-shares to Jiang Pharmaceutical Holdings will not change the control of the company, as they will remain the controlling shareholder [6]